1105039-88-0

Basic information

• Product Name: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• Synonyms: 1-[(4-methoxyphenyl)methyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-Pyrazole;1-[(4-methoxyphenyl)methyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
• CAS NO: 1105039-88-0
• Molecular Formula: C₁₇H₂₃BN₂O₃
• Molecular Weight: 314.18712
• Mol File: 1105039-88-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1105039-88-0)
• EPA Substance Registry System: 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(1105039-88-0)

Safety Data

• Hazardous Substances Data: 1105039-88-0(Hazardous Substances Data)

Usage

General Description

1-(4-Methoxybenzyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is a specialty chemical compound, often used in pharmaceutical and chemical research. Its molecular structure is comprised of a pyrazole ring, which is a simple aromatic ring composing of two nitrogen atoms, a methoxybenzyl moiety and a tetramethyl-1,3,2-dioxaborolane fragment. 1-(4-Methoxybenzyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is specifically designed to optimize reactivity in various chemical processes such as Suzuki-Miyaura coupling, thus it has the potential be utilized as an intermediate in the synthesis of complex molecular structures. Specific data about this chemical could include its molecular weight, melting point, boiling point, flash point and solubility in various solvents.

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1105039-89-1 2-bromo-6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)pyridine 
• 1262849-05-7 2-(4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)thiazol-2-yloxy)pyridine 
• 1590410-77-7 C₂₄H₁₈F₃N₅O₃ 
• 1590410-76-6 C₃₁H₂₄F₃N₅O₃ 
• 1449669-02-6 N-(2-ethyl-4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)phenyl)-N, 1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449669-01-5 N-(2-ethyl-4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)phenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449669-00-4 2-ethyl-4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)aniline 
• 1315566-73-4 N-(5-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-1,2,4-thiadiazol-3-yl)pyridin-2-amine 
• 1315566-72-3 5-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-3-chloro-1,2,4-thiadiazole 

Relevant articles and documents

3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein M, P, X1, X2, (A)m and (B)n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtyp